Targeting Macrophages: Therapeutic Approaches in Cancer

Overview

Journal Nat Rev Drug Discov

Specialty Pharmacology

Date 2018 Oct 27

PMID 30361552

Citations 890

Authors

Luca Cassetta

Jeffrey W Pollard

Affiliations

Soon will be listed here.

Abstract

Infiltration of macrophages in solid tumours is associated with poor prognosis and correlates with chemotherapy resistance in most cancers. In mouse models of cancer, macrophages promote cancer initiation and malignant progression by stimulating angiogenesis, increasing tumour cell migration, invasion and intravasation and suppressing antitumour immunity. At metastatic sites, macrophages promote tumour cell extravasation, survival and subsequent growth. Each of these pro-tumoural activities is promoted by a subpopulation of macrophages that express canonical markers but have unique transcriptional profiles, which makes tumour-associated macrophages (TAMs) good targets for anticancer therapy in humans through either their ablation or their re-differentiation away from pro-tumoural towards antitumoural states. In this Review, we evaluate the state of the art of TAM-targeting strategies, focusing on the limitations and potential side effects of the different therapies such as toxicity, rebound effects and compensatory mechanisms. We provide an extensive overview of the different types of therapy used in the clinic and their limitations in light of known macrophage biology and propose new strategies for targeting TAMs.

Citing Articles

Bacterial-Mediated In Situ Engineering of Tumour-Associated Macrophages for Cancer Immunotherapy.

Kuhl G, Tangney M Cancers (Basel). 2025; 17(5).

PMID: 40075571 PMC: 11899205. DOI: 10.3390/cancers17050723.

Targeting cGAS-STING pathway for reprogramming tumor-associated macrophages to enhance anti-tumor immunotherapy.

Zhang W, Huang X Biomark Res. 2025; 13(1):43.

PMID: 40075527 PMC: 11905658. DOI: 10.1186/s40364-025-00750-w.

Tebentafusp, a T cell engager, promotes macrophage reprogramming and in combination with IL-2 overcomes macrophage immunosuppression in cancer.

Guc E, Treveil A, Leach E, Broomfield A, Camera A, Clubley J Nat Commun. 2025; 16(1):2374.

PMID: 40064880 PMC: 11893752. DOI: 10.1038/s41467-025-57470-w.

Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets.

Guan F, Wang R, Yi Z, Luo P, Liu W, Xie Y Signal Transduct Target Ther. 2025; 10(1):93.

PMID: 40055311 PMC: 11889221. DOI: 10.1038/s41392-025-02124-y.

Myeloid cells: key players in tumor microenvironments.

Hua Q, Li Z, Weng Y, Wu Y, Zheng L Front Med. 2025; .

PMID: 40048137 DOI: 10.1007/s11684-025-1124-8.

References

Morandi F, Pistoia V . Interactions between HLA-G and HLA-E in Physiological and Pathological Conditions. Front Immunol. 2014; 5:394. PMC: 4141331. DOI: 10.3389/fimmu.2014.00394. View

Gao D, Joshi N, Choi H, Ryu S, Hahn M, Catena R . Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition. Cancer Res. 2012; 72(6):1384-94. PMC: 8543151. DOI: 10.1158/0008-5472.CAN-11-2905. View

Sotsios Y, Ward S . Phosphoinositide 3-kinase: a key biochemical signal for cell migration in response to chemokines. Immunol Rev. 2001; 177:217-35. DOI: 10.1034/j.1600-065x.2000.17712.x. View

Bergamaschi A, Tagliabue E, Sorlie T, Naume B, Triulzi T, Orlandi R . Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J Pathol. 2007; 214(3):357-67. DOI: 10.1002/path.2278. View

Sharma P, Allison J . Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015; 161(2):205-14. PMC: 5905674. DOI: 10.1016/j.cell.2015.03.030. View

Smith H, Stephens N, Qualls C, Fligelman T, Wang T, Lin C . The clinical significance of inflammatory cytokines in primary cell culture in endometrial carcinoma. Mol Oncol. 2012; 7(1):41-54. PMC: 3790272. DOI: 10.1016/j.molonc.2012.07.002. View

Zhu Y, Herndon J, Sojka D, Kim K, Knolhoff B, Zuo C . Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor Progression. Immunity. 2017; 47(3):597. PMC: 5664180. DOI: 10.1016/j.immuni.2017.08.018. View

Singh M, Khong H, Dai Z, Huang X, Wargo J, Cooper Z . Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation. J Immunol. 2014; 193(9):4722-31. PMC: 4201984. DOI: 10.4049/jimmunol.1401160. View

Mbongue J, Nicholas D, Torrez T, Kim N, Firek A, Langridge W . The Role of Indoleamine 2, 3-Dioxygenase in Immune Suppression and Autoimmunity. Vaccines (Basel). 2015; 3(3):703-29. PMC: 4586474. DOI: 10.3390/vaccines3030703. View

10.

Hoves S, Ooi C, Wolter C, Sade H, Bissinger S, Schmittnaegel M . Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity. J Exp Med. 2018; 215(3):859-876. PMC: 5839760. DOI: 10.1084/jem.20171440. View

11.

Tang R, Beuvon F, Ojeda M, Mosseri V, Pouillart P, Scholl S . M-CSF (monocyte colony stimulating factor) and M-CSF receptor expression by breast tumour cells: M-CSF mediated recruitment of tumour infiltrating monocytes?. J Cell Biochem. 1992; 50(4):350-6. DOI: 10.1002/jcb.240500403. View

12.

Camacho D, Pienta K . A multi-targeted approach to treating bone metastases. Cancer Metastasis Rev. 2014; 33(2-3):545-53. DOI: 10.1007/s10555-013-9476-y. View

13.

Liu R, Wei H, Gao P, Yu H, Wang K, Fu Z . CD47 promotes ovarian cancer progression by inhibiting macrophage phagocytosis. Oncotarget. 2017; 8(24):39021-39032. PMC: 5503592. DOI: 10.18632/oncotarget.16547. View

14.

Quail D, Joyce J . Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013; 19(11):1423-37. PMC: 3954707. DOI: 10.1038/nm.3394. View

15.

Amarante-Mendes G, Griffith T . Therapeutic applications of TRAIL receptor agonists in cancer and beyond. Pharmacol Ther. 2015; 155:117-31. PMC: 4955572. DOI: 10.1016/j.pharmthera.2015.09.001. View

16.

Zhang Q, Liu L, Gong C, Shi H, Zeng Y, Wang X . Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS One. 2013; 7(12):e50946. PMC: 3532403. DOI: 10.1371/journal.pone.0050946. View

17.

Rodan G, Fleisch H . Bisphosphonates: mechanisms of action. J Clin Invest. 1996; 97(12):2692-6. PMC: 507360. DOI: 10.1172/JCI118722. View

18.

Lebrecht A, Grimm C, Lantzsch T, Ludwig E, Hefler L, Ulbrich E . Monocyte chemoattractant protein-1 serum levels in patients with breast cancer. Tumour Biol. 2004; 25(1-2):14-7. DOI: 10.1159/000077718. View

19.

Gomez Perdiguero E, Geissmann F . The development and maintenance of resident macrophages. Nat Immunol. 2015; 17(1):2-8. PMC: 4950995. DOI: 10.1038/ni.3341. View

20.

Chitu V, Stanley E . Colony-stimulating factor-1 in immunity and inflammation. Curr Opin Immunol. 2005; 18(1):39-48. DOI: 10.1016/j.coi.2005.11.006. View